drugset / Trial / NCT06139055
A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
Phase 1
Unknown
70 enrolled
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.
Timeline
- Start
- 2023-10-02
- Primary completion
- 2024-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aleniglipron | Small molecule | — | Oral |
Indications
No indication recorded.